Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone

Archives of Ophthalmology

Volumn 125, Issue 6, 2007, Pages 759-764

  Scorolli, Lucia ^a   Morara, Mariachiara ^a   Meduri, Alessandro ^a   Reggiani, Letizia Bacchi ^a   Ferreri, Giuseppe ^b   Scalinci, Sergio Z ^a   Meduri, Renato A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; RETINA MACULA LUTEA; RETINITIS PIGMENTOSA; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; CORNEA; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR EDEMA, CYSTOID; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINITIS PIGMENTOSA; TOMOGRAPHY, OPTICAL COHERENCE; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 34250380359     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.125.6.759     Document Type: Article

References (48)

1. RetNet Retinal Information Network Web site. www.sph.uth.tmc.edu/retnet. Accessed June 2006.
2. Wang DY, Chan WM, Tam PO, et al. Gene mutations in retinitis pigmentosa and their clinical implications. Clin Chim Acta. 2005;351:5-16.
3. Wang DY, Chan WM, Tam PO, et al. Genetic markers for retinitis pigmentosa. Hong Kong Med J. 2005;11:281-288.
4. Kalloniatis M, Fletcher EL. Retinitis pigmentosa: understanding the clinical presentation, mechanisms and treatment options. Clin Exp Optom. 2004;87:65-80.
5. John SK, Smith JE, Aguirre GD, Milam AH. Loss of cone molecular markers in rhodopsin-mutant human retinas with retinitis pigmentosa. Mol Vis. 2000;6:204-215.
6. Alexander KR, Rajagopalan AS, Raghuram A, Fishman GA. Activation phase of cone phototransduction and the flicker electroretinogram in retinitis pigmentosa. Vision Res. 2006;46:2773-2785.
7. Fishman GA, Maggiano JM, Fishman M. Foveal lesion seen in RP. Arch Ophthalmol. 1977;95:1993-1996.
8. Moldow B, Sander B, Larsen M, et al. The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema. Graefes Arch Clin Exp Ophthalmol. 1998;236:881-889.
9. Giusti C, Forte R, Vingolo EM. Deflazacort treatment of cystoid macular edema in patients affected by retinitis pigmentosa: a pilot study. Eur Rev Med Pharmacol Sci. 2002;6:1-8.
10. García-Arumí J, Martinez V, Sararols L, Corcostegui B. Vitreoretinal surgery for cystoid macular edema associated with retinitis pigmentosa. Ophthalmology. 2003;110:1164-1169.
11. Fishman GA, Gilbert LD, Fiscella G, Kimura AE, Jampol LM. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol. 1989;107:1445-1452.
12. Newsome DA, Blacharski PA. Grid photocoagulation for macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 1987;103:161-166.
13. Ozdemir H, Karacorlu M, Karacorlu S. Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmol Scand. 2005;83:248-251.
14. Heckenlively JR, Solish AM, Chant SM, Meyers-Elliott RH. Autoimmunity in hereditary retinal degenerations, II: clinical studies: antiretinal antibodies and fluorescein angiogram findings. Br J Ophthalmol. 1985;69:758-764.
15. Rogers SW, Andrews PI, Gahring LC, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science. 1994;265:648-651.
16. el Far O, Marqueze B, Leveque C, et al. Antigens associated with N- and L-type calcium channels in Lambert-Eaton myasthenic syndrome. J Neurochem. 1995;64:1696-1702.
17. Moodie FD, Leaker B, Cambridge G, Totty NF, Segal AW. Alpha enolase: a novel cytosolic autoantigen in ANCA positive vasculitis. Kidney Int. 1993;43:675-681.
18. Jackson J, Feighery C. Autoimmune angioedema: a new role for autoantibody in disease pathogenesis. Autoimmunity. 1990;7:181-187.
19. Mandle R, Baron C, Roux E, et al. Acquired C1 inhibitor deficiency as a result of an autoantibody to the reactive center region of C1 inhibitor. J Immunol. 1994;152:4680-4685.
20. Inagaki Y, Jinno-Yoshida Y, Hamasaki Y, Ueki H. A novel autoantibody reactive with carbonic anhydrase in sera from patients with systemic lupus erythematosus and Sjogren syndrome. J Dermatol Sci. 1991;2:147-154.
21. Itoh Y, Reichlin M. Antibodies to carbonic anhydrase in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 1992;35:73-82.
22. Kiechle FL, Quattrociocchi-Longe TM, Brinton DA. Carbonic anhydrase antibody in sera from patients with endometriosis. Am J Clin Pathol. 1994;101:611-615.
23. Heckenlively JR, Jordan BL, Aptsiauri N. Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 1999;127:565-573.
24. Wolfensberger TJ, Aptsiauri N, Godley B, Downes S, Bird AC. Antiretinal antibodies associated with cystoid macular edema [in German]. Klin Monatsbl Augenheilkd. 2000;216:283-285.
25. Chant SM, Heckenlively JR, Meyers-Elliott RH. Autoimmunity in hereditary retinal degeneration, I: basic studies. Br J Ophthalmol. 1985;69:19-24.
26. Jonas JB, Hayler A, Sofker JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2001;131:468-471.
27. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003;136:791-796.
28. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol. 2003;121:1279-1282.
29. Penfold PL, Wen L, Madigan MC, Gillies MC, King NJ, Provis JM. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line implications for macular degeneration. Clin Exp Immunol. 2000;121:458-465.
30. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for age related macular degeneration. Br J Ophthalmol. 2003;87:462-468.
31. Karacorlu M, Ozdemir H, Karacorlu S. Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic macular oedema. Acta Ophthalmol Scand. 2003;81:648-652.
32. McCartney HJ, Drysdale IO, Gornall AG, Basu PK. An autoradiographic study of the penetration of subconjunctivally injected hydrocortisone into the normal and inflamed rabbit eye. Invest Ophthalmol. 1965;4:297-302.
33. Tessler H, Lam S. Cystoid macular edema. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular Infection and Immunity. St Louis, Mo: CV Mosby; 1996:553-589.
34. Wakefield D, McCluskey P, Penny R. Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease. Arch Ophthalmol. 1986;104:847-851.
35. Tehrani NN, Saeed T, Murray PI. Deep intramuscular methylprednisolone for the treatment of cystoid macular oedema in uveitis. Eye. 2000;14(pt 5):691-694.
36. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000;84:1064-1067.
37. Jonas JB. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol. 2004;137:560-562.
38. Yeung CK, Chan KP, Chan CK, Pang CP, Lam DS. Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone. Jpn J Ophthalmol. 2004;48:236-242.
39. Yeung CK, Chan KP, Chiang SW, Pang CP, Lam DS. The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest Ophthalmol Vis Sci. 2003;44:5293-5300.
40. Narayanan R, Mungcal JK, Kenney MC, Seigel GM, Kuppermann BD. Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest Ophthalmol Vis Sci. 2006;47:722-728.
41. Bakri SJ, Beer PM. Choroidal neovascularization after radial optic neurotomy for central retinal vein occlusion. Retina. 2004;24:610-611.
42. Hirakawa H, Iijima H, Gohdo T, Tsukahara S. Optical coherence tomography of cystoid macular edema associated with retinitis pigmentosa. Am J Ophthalmol. 1999;128:185-191.
43. Stanga PE, Downes SM, Ahuja RM, et al. Comparison of optical coherence tomography and fluorescein angiography in assessing macular edema in retinal dystrophies: preliminary results. Int Ophthalmol. 2001;23:321-325.
44. Apushkin MA, Fishman GA, Janowicz MJ. Monitoring cystoid macular edema by optical coherence tomography in patients with retinitis pigmentosa. Ophthalmology. 2004;111:1899-1904.
45. Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I, Pavesio CE. Macular edema. Surv Ophthalmol. 2004;49:470-490.
46. Kylstra JA, Wierzbicki T, Wolbarsht ML, Landers MB III, Stefansson E. The relationship between retinal vessel tortuosity, diameter, and transmural pressure. Graefes Arch Clin Exp Ophthalmol. 1986;224:477-480.
47. Molnar I, Poitry S, Tsacopoulos M, Gilodi N, Leuenberger PM. Effect of laser photocoagulation on oxygenation of the retina in miniature pigs. Invest Ophthalmol Vis Sci. 1985;26:1410-1414.
48. Moorman CM, Hamilton AM. Clinical applications of the MicroPulse diode laser. Eye. 1999;13(pt 2):145-150.